MetVital is raising $10 mln for its phase2A clinical trial to treat brain cancer

MetVital, Inc CEO Alan Cash talks about the exciting potential of oxaloacetate.

MetVital, Inc CEO Alan Cash sat down with Proactive at the BIO Investor Forum in San Francisco. 

The San Diego-based biopharmaceutical company is developing small molecule modulators of glutamate metabolism for the treatment of diseases like brain cancer.

Leave a comment

Your email address will not be published. Required fields are marked *